Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL6306849 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL2138391 | 0.76 | HIF1A (0.60) | HIF1AMAPTPDE4AKDRCXCR4 | |
| SCHEMBL3468223 | 0.76 | — | — | |
| Piperazine SCHEMBL9441873 | 0.72 | HIF1A (0.55) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL11837613 | 0.71 | — | — | |
| Piperazine SCHEMBL964330 | 0.66 | HIF1A (0.75) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL2136219 | 0.66 | — | — | |
| Aziridine SCHEMBL8528843 | 0.66 | — | — | |
| Piperazine SCHEMBL11729197 | 0.66 | HIF1A (0.75) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Aziridine SCHEMBL28314657 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115845169-A | Device for maintaining metal in stable state and use thereof | 梅克布朗公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4146297-A1 | DIALYSIS SYSTEM FOR TREATING SEPSIS | Mexbrain (FR) | 2023-03-15 | — | — | EP | disclosed |
| US-20220288206-A1 | NANOPARTICLES FOR THE TREATMENT OF CANCER BY RADIOFREQUENCY RADIATION | LYON INGENIERIE PROJETS (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-4013511-A1 | NANOPARTICLES FOR THE TREATMENT OF CANCER BY RADIOFREQUENCY RADIATION | NH THERAGUIX (FR) | 2022-06-22 | — | — | EP | disclosed |
| EP-3914298-A1 | DEVICE FOR JOINT EXTRACTION OF A METAL CATION AND A TARGET MOLECULE | Mexbrain (FR) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021028642-A1 | NANOPARTICLES FOR THE TREATMENT OF CANCER BY RADIOFREQUENCY RADIATION | NH THERAGUIX (FR) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288206-A1 | NANOPARTICLES FOR THE TREATMENT OF CANCER BY RADIOFREQUENCY RADIATION | HSP90AA1, HSP90AB1, NQO2 | HIF1A 36/4885MAPT 3380/4885PDE4A 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.